Compound Detail
CHEMBL1009
LEVODOPA 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1009 |
| Name | LEVODOPA |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | WTDRDQBEARUVNC-LURJTMIESA-N |
| Therapeutic | ✓ Yes |
| Active Moiety | CHEMBL59 |
7
Targets
10
Activities
2
Assay Types
30
PK Parameters
20
Publications
23
Known Names
20
Indications
1
Mechanisms
Molecular Properties
197.2
MW (Da)
0.05
ALogP
4
HBA
4
HBD
103.8
PSA (Ų)
0.51
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1970 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Dopamine D3 receptor agonist | AGONIST | D(3) dopamine receptor | ✓ | ✓ |
Indications
Parkinson Disease Amblyopia Restless Legs Syndrome Stroke Albinism Albinism, Oculocutaneous Angelman Syndrome Aphasia Back Pain Child Development Disorders, Pervasive Chronic Pain Cocaine-Related Disorders Cocaine-Related Disorders Macular Degeneration Pain Retinitis Pigmentosa Schizophrenia Spinal Cord Injuries Stress Disorders, Post-Traumatic Amyotrophic Lateral Sclerosis
ATC Classification
N04BA01
levodopa
Level 1: NERVOUS SYSTEM
Level 2: ANTI-PARKINSON DRUGS
Activity Summary
IC50 9 meas. best 6.28
Kd 1 meas. best 4.72
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Unchecked CHEMBL612545 | IC50 | 6.28 | 6.28 | 526.1 | 1 |
| Tyrosine-protein kinase Fyn CHEMBL1841 | IC50 | 5.67 | 5.67 | 2146.0 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 CHEMBL4358 | IC50 | 5.65 | 5.65 | 2258.0 | 1 |
| Epidermal growth factor receptor CHEMBL203 | IC50 | 5.54 | 5.54 | 2880.0 | 1 |
| Tyrosine-protein kinase Lck CHEMBL258 | IC50 | 5.43 | 5.43 | 3729.0 | 1 |
| Mushroom tyrosinase CHEMBL6066154 | Kd | 4.72 | 4.72 | 19000.0 | 1 |
| Large neutral amino acids transporter small subunit 1 CHEMBL4459 | IC50 | 4.0 | 4.0 | 100000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 117730.0 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 23.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 109.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 17.0 | mL.min-1.kg-1 | Macaca |
| CL | 19.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 23.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 23.0 | mL.min-1.kg-1 | Homo sapiens |
| Cmax | 1120.0 | nM | Mus musculus |
| Cmax | 4730.0 | nM | Mus musculus |
| Cmax | 16200.0 | nM | Mus musculus |
| Cmax | 52000.0 | nM | Rattus norvegicus |
| Cmax | 9500.0 | nM | Simiiformes |
| Cmax | 8100.0 | nM | Simiiformes |
| Cmax | 28551.14 | nM | Rattus norvegicus |
| F | 33.0 | % | Eutheria |
| F | 100.0 | % | Homo sapiens |
| Fu | 0.76 | - | Homo sapiens |
| KA | 43.0 | uM | Mus musculus |
| KA | 11.4 | uM | Homo sapiens |
| KA | 3.1 | uM | Homo sapiens |
| KA | 3.1 | uM | Homo sapiens |
| KA | 11.4 | uM | Homo sapiens |
| KA | 58.3 | uM | Homo sapiens |
| KA | 12.1 | uM | Homo sapiens |
| KA | 0.036 | uM | Homo sapiens |
| KA | 0.063 | uM | Homo sapiens |
| Ka | 3.1 | uM | Homo sapiens |
| Ka | 11.4 | uM | Homo sapiens |
| Ka | 18.0 | uM | Homo sapiens |
| KA | 3.1 | uM | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine